Oseltamivir - Roche

Drug Profile

Oseltamivir - Roche

Alternative Names: EN 241104; GS 4104; GS 4104-002; Ke Wei; Kewei; Oseltamivir phosphate; RO 640796; RO 640796/002; Tamiflu; Tamiflu Dry Syrup

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Australian National University; Gilead Sciences; University of California at Berkeley
  • Developer Chugai Pharmaceutical; HEC Pharm; Roche
  • Class Acetamides; Antivirals; Cyclohexenes; Esters; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 21 Apr 2018 Adverse events data from a phase IIIb trial in Influenza virus infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 02 May 2017 Roche initiates completes a phase III trialb for Influenza virus infections in the US, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Estonia, France, Germany, Guatemala, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Poland, South Africa, Romania, Spain, Switzerland, Ukraine and the UK (NCT00545532)
  • 16 Dec 2016 Preregistration for Influenza virus infections (In infants, In neonates) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top